Related Experiment Video

Updated: Apr 17, 2026

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells
10:06

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells

Published on: April 26, 2017

9.5K

CLK2 Is an Oncogenic Kinase and Splicing Regulator in Breast Cancer

Taku Yoshida1, Jee Hyun Kim2, Kristopher Carver1

  • 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Department of Medicine, Harvard Medical School, Boston, Massachusetts. Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.

Cancer Research
|February 12, 2015
PubMed

Insights

CLK2, a splicing kinase, drives breast cancer growth and metastasis. Inhibiting CLK2 shows promise for new breast cancer therapies by targeting oncogenic splicing patterns and epithelial-to-mesenchymal transition.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • Genetically activated kinases are promising cancer therapeutic targets.
  • Aberrant alternative splicing is common in human cancers, but mechanisms are unclear.
  • CLK2 (CDC-like kinase 2) is amplified and overexpressed in breast tumors.

Purpose of the Study:

  • To identify novel oncogenic kinases in breast cancer.
  • To investigate the role of CLK2 in breast cancer progression and splicing.

Main Methods:

  • Conducted a lentiviral shRNA cell viability screen of 26 amplified/overexpressed genes in breast cancer cell lines.
  • Analyzed the effect of CLK2 downregulation on cell growth, migration, and invasion.
  • Examined gene expression and alternative splicing patterns, including epithelial-to-mesenchymal transition (EMT)-related genes.

Main Results:

  • CLK2 was identified as an oncogene in breast cancer.
  • Downregulation of CLK2 inhibited breast cancer cell growth in vitro and in vivo (xenograft models).
  • Loss of CLK2 promoted cell migration and invasion, upregulating EMT-related genes and mesenchymal splice variants like ENAH (MENA).

Conclusions:

  • CLK2 acts as an oncogene in breast cancer by influencing splicing patterns.
  • Targeting CLK2 may offer a therapeutic strategy to inhibit breast tumor growth and modulate EMT.
  • Understanding CLK2's role in alternative splicing provides insights into cancer progression.

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.9K
Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer07:13

Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer

Published on: March 26, 2014

24.1K

Related Concept Videos

Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
10.5K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

3.1K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
12.2K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

6.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.8K